Kyntra Bio develops cancer and anemia treatments, including a prostate cancer drug candidate and roxadustat, from San Francisco. It last closed at $1.56 on Nov 20, down 14.75% on the day. The next earnings report for KYNB is expected around Mon, Mar 15, 2027, after the close. For the quarter ended Sep 2026, KYNB reported EPS of $0.04 on revenue of $1.8M, with revenue up 63.8% from a year ago. Over its last 6 reports the stock moved an average of 11.3% the session after earnings.
AI Auto Pilots
Is KYNB in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold KYNB.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on KYNBStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
KYNB · as of the Nov 20 close · updated each morning
Downtrend, oversold
The stock is 130% below its 20 day and 236% below its 50 day average. It is 330% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 12), oversold. The nearest support is the Pivot S1 at $1.46, and the nearest resistance the Pivot at $1.66.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 28.1%/day
Key levels
$10.4752 week high+571.2%
$6.71200 day average+330.1%
$6.33100 day average+305.8%
$5.2450 day average+235.9%
$4.85Swing high (Oct 29)+210.9%
$3.5920 day average+130.1%
$1.75Pivot R1+12.2%
$1.66Pivot+6.4%
$1.5652 week low+0.0%
$1.56Last close
$1.46Pivot S1−6.4%
Indicators
RSI (14)
12.17
Oversold below 30
Oversold
MACD
-0.94
Below its signal line
Bearish
Stochastic
1.9
Near the bottom of its range
Oversold
ADX (14)
51.8
Strong downtrend
Williams %R
-99.9
Oversold below −80, overbought above −20
Oversold
CCI (20)
-180.2
Oversold below −100, overbought above 100
Oversold
Rate of change
−58.2%
Change over 10 sessions
Bearish
ATR (14)
$0.44
Typical daily range, 28.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Falling, oversold
Short trendBearish
Long trendNot enough history
MomentumWeak
StretchOversold
VolatilityHigh, 60.8%/day
Key levels
$10.4752 week high+571.2%
$6.71200 day average+330.1%
$6.33100 day average+305.8%
$5.2450 day average+235.9%
$4.85Swing high (Oct 29)+210.9%
$3.5920 day average+130.1%
$1.75Pivot R1+12.2%
$1.66Pivot+6.4%
$1.5652 week low+0.0%
$1.56Last close
$1.46Pivot S1−6.4%
Indicators
RSI (14)
18.60
Oversold below 30
Oversold
MACD
-1.13
Below its signal line
Bearish
Stochastic
1.5
Near the bottom of its range
Oversold
ADX (14)
28.4
Trending down
Williams %R
-99.9
Oversold below −80, overbought above −20
Oversold
CCI (20)
-201.1
Oversold below −100, overbought above 100
Oversold
Rate of change
−80.4%
Change over 10 sessions
Bearish
ATR (14)
$0.95
Typical daily range, 60.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100–
MA 200–
What happened before, for KYNB
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how KYNB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow KYNB usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for KYNBHow many large options trades hit KYNB, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in KYNB in the last 90 days.
From SEC Form 4 filings by KYNB's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether KYNB is in one of them and how their past KYNB trades turned out.
Kyntra Bio is a biopharmaceutical company in San Francisco, California, that develops treatments for cancer and anemia. Its lead program, FG-3246, is a drug candidate for advanced prostate cancer, paired with FG-3180, an imaging agent that helps identify suitable patients. The company also holds rights to roxadustat, a treatment for anemia in patients with chronic kidney disease, and is developing it for a blood disorder called myelodysplastic syndromes.